Frontiers in Immunology (Feb 2024)
CD8+ NKs as a potential biomarker of complete response and survival with lenalidomide plus R-GDP in the R2-GDP-GOTEL trial in recurrent/refractory diffuse large B cell lymphoma
- Lourdes Hontecillas-Prieto,
- Lourdes Hontecillas-Prieto,
- Lourdes Hontecillas-Prieto,
- Lourdes Hontecillas-Prieto,
- Daniel J. García-Domínguez,
- Daniel J. García-Domínguez,
- Natalia Palazón-Carrión,
- Natalia Palazón-Carrión,
- Alejandro Martín García-Sancho,
- Esteban Nogales-Fernández,
- Esteban Nogales-Fernández,
- Carlos Jiménez-Cortegana,
- María L. Sánchez-León,
- Silvia Silva-Romeiro,
- Rocío Flores-Campos,
- Fernando Carnicero-González,
- Eduardo Ríos-Herranz,
- Fátima de la Cruz-Vicente,
- Guillermo Rodríguez-García,
- Rubén Fernández-Álvarez,
- Natividad Martínez-Banaclocha,
- Josep Gumà-Padrò,
- José Gómez-Codina,
- Antonio Salar-Silvestre,
- Delvys Rodríguez-Abreu,
- Laura Gálvez-Carvajal,
- Jorge Labrador,
- María Guirado-Risueño,
- Mariano Provencio-Pulla,
- Margarita Sánchez-Beato,
- Lejeune Marylene,
- Tomás Álvaro-Naranjo,
- María Casanova-Espinosa,
- Antonio Rueda-Domínguez,
- Víctor Sánchez-Margalet,
- Víctor Sánchez-Margalet,
- Víctor Sánchez-Margalet,
- Luis de la Cruz-Merino,
- Luis de la Cruz-Merino,
- Luis de la Cruz-Merino
Affiliations
- Lourdes Hontecillas-Prieto
- Clinical Biochemistry Service, Virgen Macarena University Hospital, University of Seville, Seville, Spain
- Lourdes Hontecillas-Prieto
- Department of Medical Biochemistry and Molecular Biology and Immunology, Medical School, Virgen Macarena University Hospital, University of Seville, Seville, Spain
- Lourdes Hontecillas-Prieto
- Institute of Biomedicine of Seville, Virgen Macarena University Hospital, CSIC, University of Seville, Seville, Spain
- Lourdes Hontecillas-Prieto
- Clinical Oncology Service, Hospital Universitario Virgen Macarena, University of Seville, Seville, Spain
- Daniel J. García-Domínguez
- Department of Medical Biochemistry and Molecular Biology and Immunology, Medical School, Virgen Macarena University Hospital, University of Seville, Seville, Spain
- Daniel J. García-Domínguez
- Institute of Biomedicine of Seville, Virgen Macarena University Hospital, CSIC, University of Seville, Seville, Spain
- Natalia Palazón-Carrión
- Clinical Oncology Service, Hospital Universitario Virgen Macarena, University of Seville, Seville, Spain
- Natalia Palazón-Carrión
- Department of Medicine, University of Seville, Seville, Spain
- Alejandro Martín García-Sancho
- Department of Hematology, Hospital Universitario de Salamanca, IBSAL, CIBERONC, University of Salamanca, Salamanca, Spain
- Esteban Nogales-Fernández
- Clinical Oncology Service, Hospital Universitario Virgen Macarena, University of Seville, Seville, Spain
- Esteban Nogales-Fernández
- Department of Medicine, University of Seville, Seville, Spain
- Carlos Jiménez-Cortegana
- Department of Medical Biochemistry and Molecular Biology and Immunology, Medical School, Virgen Macarena University Hospital, University of Seville, Seville, Spain
- María L. Sánchez-León
- Clinical Oncology Service, Hospital Universitario Virgen Macarena, University of Seville, Seville, Spain
- Silvia Silva-Romeiro
- Clinical Oncology Service, Hospital Universitario Virgen Macarena, University of Seville, Seville, Spain
- Rocío Flores-Campos
- Clinical Oncology Service, Hospital Universitario Virgen Macarena, University of Seville, Seville, Spain
- Fernando Carnicero-González
- Department of Hematology, Hospital San Pedro de Alcántara de Cáceres, Cáceres, Spain
- Eduardo Ríos-Herranz
- Department of Hematology, Hospital Universitario de Valme, Seville, Spain
- Fátima de la Cruz-Vicente
- Department of Hematology, Hospital Universitario Virgen del Rocío, Seville, Spain
- Guillermo Rodríguez-García
- Department of Hematology, Hospital Universitario Virgen del Rocío, Seville, Spain
- Rubén Fernández-Álvarez
- 0Department of Hematology, Cabueñes Hospital, Gijón, Spain
- Natividad Martínez-Banaclocha
- 1Oncology Dept., Dr. Balmis General University Hospital, Alicante Institute for Health and Biomedical Research (ISABIAL), Alicante, Spain
- Josep Gumà-Padrò
- 2Department of Clinical Oncology, Hospital Universitari Sant Joan de Reus URV, IISPV, Reus, Spain
- José Gómez-Codina
- 3Department of Clinical Oncology, Hospital Universitario La Fé, Valencia, Spain
- Antonio Salar-Silvestre
- 4Department of Hematology, Hospital del Mar, Barcelona, Spain
- Delvys Rodríguez-Abreu
- 5Department of Clinical Oncology, Hospital Universitario Insular, Las Palmas de Gran Canaria, Spain
- Laura Gálvez-Carvajal
- 6Department of Medical Oncology Intercenter Unit, Regional and Virgen de la Victoria University Hospitals, IBIMA, Málaga, Spain
- Jorge Labrador
- 7Department of Hematology, Research Unit, Hospital Universitario de Burgos, Burgos, Spain
- María Guirado-Risueño
- 8Department of Clinical Oncology, Hospital General Universitario de Elche, Elche, Spain
- Mariano Provencio-Pulla
- 9Department of Medical Oncology, Hospital Universitario Puerta de Hierro-Majadahonda, Facultad de Medicina, Universidad Autónoma de Madrid, IDIPHISA, Madrid, Spain
- Margarita Sánchez-Beato
- 0Department of Medical Oncology, Lymphoma Research Group, Hospital Universitario Puerta de Hierro-Majadahonda, IDIPHISA, CIBERONC, Madrid, Spain
- Lejeune Marylene
- 1Department of Pathology, Plataforma de Estudios Histológicos, Citológicos y de Digitalización, Hospital de Tortosa Verge de la Cinta, IISPV, URV, Tortosa, Tarragona, Spain
- Tomás Álvaro-Naranjo
- 2Department of Pathology, Hospital de Tortosa Verge de la Cinta, Catalan Institute of Health, Institut d’Investigació Sanitària Pere Virgili (IISPV), Tortosa, Tarragona, Spain
- María Casanova-Espinosa
- 3Department of Hematology/Clinical Oncology, Hospital Costa del Sol, Marbella, Spain
- Antonio Rueda-Domínguez
- 3Department of Hematology/Clinical Oncology, Hospital Costa del Sol, Marbella, Spain
- Víctor Sánchez-Margalet
- Clinical Biochemistry Service, Virgen Macarena University Hospital, University of Seville, Seville, Spain
- Víctor Sánchez-Margalet
- Department of Medical Biochemistry and Molecular Biology and Immunology, Medical School, Virgen Macarena University Hospital, University of Seville, Seville, Spain
- Víctor Sánchez-Margalet
- Institute of Biomedicine of Seville, Virgen Macarena University Hospital, CSIC, University of Seville, Seville, Spain
- Luis de la Cruz-Merino
- Institute of Biomedicine of Seville, Virgen Macarena University Hospital, CSIC, University of Seville, Seville, Spain
- Luis de la Cruz-Merino
- Clinical Oncology Service, Hospital Universitario Virgen Macarena, University of Seville, Seville, Spain
- Luis de la Cruz-Merino
- Department of Medicine, University of Seville, Seville, Spain
- DOI
- https://doi.org/10.3389/fimmu.2024.1293931
- Journal volume & issue
-
Vol. 15
Abstract
BackgroundDiffuse large B cell lymphoma (DLBCL) is the most common non-Hodgkin lymphoma worldwide. DLBCL is an aggressive disease that can be cured with upfront standard chemoimmunotherapy schedules. However, in approximately 35-40% of the patients DLBCL relapses, and therefore, especially in this setting, the search for new prognostic and predictive biomarkers is an urgent need. Natural killer (NK) are effector cells characterized by playing an important role in antitumor immunity due to their cytotoxic capacity and a subset of circulating NK that express CD8 have a higher cytotoxic function. In this substudy of the R2-GDP-GOTEL trial, we have evaluated blood CD8+ NK cells as a predictor of treatment response and survival in relapsed/refractory (R/R) DLBCL patients.Methods78 patients received the R2-GDP schedule in the phase II trial. Blood samples were analyzed by flow cytometry. Statistical analyses were carried out in order to identify the prognostic potential of CD8+ NKs at baseline in R/R DLBCL patients.ResultsOur results showed that the number of circulating CD8+ NKs in R/R DLBCL patients were lower than in healthy donors, and it did not change during and after treatment. Nevertheless, the level of blood CD8+ NKs at baseline was associated with complete responses in patients with R/R DLBCL. In addition, we also demonstrated that CD8+ NKs levels have potential prognostic value in terms of overall survival in R/R DLBCL patients.ConclusionCD8+ NKs represent a new biomarker with prediction and prognosis potential to be considered in the clinical management of patients with R/R DLBCL.Clinical trial registrationhttps://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001620-29 EudraCT, ID:2014-001620-29.
Keywords
